Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

RA Diagnosis Uses Lab Tests, Clinical Insight to Rule Out Lyme

Charles Radis, DO  |  August 18, 2015

What struck me first as I walked by the exam room where Lynn P. sat was the swelling in her fingers and wrists. The bloated hands rested unnaturally on her thighs, palms up, fingers slightly flexed. Her strawberry-blond curls were offset by a high-neck, loose-fitting, burgundy sweater. Her pale skin matched her trim slacks. She had…

Filed under:ConditionsRheumatoid Arthritis Tagged with:ClinicalDiagnosislab testLyme Diseasepatient careRheumatoid arthritisrheumatologist

Biosimilar Drugs for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2015

Etanercept Biosimilars A number of Phase 3 trials are ongoing for etanercept biosimilars.1 One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsoutcomeRheumatoid arthritisrheumatologySafety

EULAR 2015: RA Research Shows Imperfect Guidelines, Suggests Strategies with Biologics

Thomas R. Collins  |  August 17, 2015

ROME, Italy—Even with classification criteria that have been updated and refined over time, rheumatoid arthritis is still a diagnosis that ultimately has to be made with clinical judgment, said Ronald van Vollenhoven, MD, PhD, professor of medicine and chief of clinical therapy research in inflammatory diseases at the Karolinska University in Sweden. His remarks came…

Filed under:ConditionsEULAR/OtherMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ClinicalDiagnosisEULARpatient carePractice ManagementResearchRheumatoid arthritis

Similar RA Outcomes with Abatacept & Tocilizumab

Will Boggs, MD  |  August 17, 2015

NEW YORK (Reuters Health)—Clinical outcomes of rheumatoid arthritis (RA) are similar with abatacept and tocilizumab treatment, but the factors that predict efficacy differ for the two agents. “The recommendations for RA treatment from the U.S. and EU describe the use of abatacept and tocilizumab as first-line biologics along with anti-TNF (anti-tumor necrosis factor) inhibitors,” Dr….

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:abataceptBiologics & BiosimilarsRheumatiod arthritistocilizumab

EULAR 2015: Biology of Fatigue Rooted in Genes, Cytokines, Free Radicals

Thomas R. Collins  |  August 17, 2015

ROME, Italy—Fatigue, a problem experienced frequently by patients with rheumatic diseases, is best thought of as a survival mechanism and as a single phenomenon, not a condition that comes in a variety of forms, an expert said in a session at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Gene Regulated…

Filed under:ConditionsEULAR/OtherMeeting ReportsResearch Rheum Tagged with:CytokinesEULARfatiguegeneResearchRheumatic Disease

Fellow’s Forum Case Report: Aneurysm in Takayasu’s Arteritis

G.C. Yathish, MD, Taral Parikh, MD, Parikshit Sagdeo, MD, Balakrishnan Canchi, MD, Gurmeet Mangat, MD, & Hemanth Kumar Pandharpurkar, MS  |  August 17, 2015

A healthy 30-year-old Indian male was performing his routine workout in the gym when he developed giddiness and transient blackouts. He thought it was due to exercising excessively. Over the next month, he developed a low-grade fever and started feeling lethargic, to the extent that he was unable to exercise or work. He was admitted…

Filed under:ConditionsVasculitis Tagged with:aneurysmsClinicalpatient carerheumatologistTakayasu’s Arteritis

Brentuximab Vedotin Enters Phase 2 Trials & More

Michele B. Kaufman, PharmD, BCGP  |  August 5, 2015

Phase 2 clinical trials have begun to assess the safety of brentuximab vedotin for the treatment of SLE. Also, the FDA is reviewing an application for a once-daily tofacitinib citrate tablet to treat RA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Brentuximab vedotinFDAMethotrexateRheumatoid Arthritis (RA)systemic lupus erythematosus (SLE)Tofacitinib

Certolizumab Pegol Effective for Treating Rheumatoid Arthritis

Reuters Staff  |  July 19, 2015

NEW YORK (Reuters Health)—Certolizumab pegol, a humanized anti-TNF antibody fragment conjugated to polyethylene glycol, is effective for treating early rheumatoid arthritis (RA) with poor prognostic factors, according to results from the C-OPERA study. Certolizumab is approved in the U.S. and other countries for treating inflammatory diseases, including RA, but its effectiveness in methotrexate-naïve early RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:anti-TNF agentCertolizumab PegolMethotrexateRheumatiod arthritis

Family History Not Linked to Clinical Presentation, Treatment Response of RA

Will Boggs, MD  |  July 16, 2015

NEW YORK (Reuters Health)—Having a family history of rheumatoid arthritis (RA) does not appear to influence the clinical presentation or treatment response of RA to standard medications, researchers from Sweden report. “At first we were a bit surprised by our findings,” Dr. Thomas Frisell from Karolinska Institutet in Stockholm told Reuters Health by email. “Patients…

Filed under:ConditionsRheumatoid Arthritis Tagged with:genetic riskgeneticsMethotrexateRheumatoid Arthritis (RA)TNF inhibitors

Polymyalgia Rheumatica Misdiagnosis Results in Positive Outcome

Hiroshi Watanabe, MD, PhD  |  July 14, 2015

In late February 2011, a 68-year-old woman visited the rheumatology outpatient clinic. She had been congenitally healthy and had been a field athlete in her early days. Beginning in early January 2011, she became aware of pain in her neck and both shoulders, with pain spreading to her lower back and thighs. She also became…

Filed under:ConditionsSoft Tissue Pain Tagged with:DiagnosisoutcomePainpatient carePolymyalgia RheumaticaTreatment

  • « Previous Page
  • 1
  • …
  • 74
  • 75
  • 76
  • 77
  • 78
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences